Oscotec Inc.

Translating science into medicine
Sign Up
PRESS
FLT3/AXL Inhibitor (A... 2020.06.22  
List of Articles
Date Website Media Pipeline
2020-05-18 Janssen Announces Phase 1 Results for Bispecific Antibody Amivantamab in the treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring Exon 20 Insertion Mutations BioSpace Lazertinib
2019-12-14 Lazertinib Shows Promising Antitumor Activity in Patients With EGFR+ NSCLC Targeted Oncology Lazertinib
2019-12-12 Yuhan to start phase-3 trial on lung cancer drug Lazertinib KBR (; Korea Biomedical Review) Lazertinib
2019-12-02 "Global Immune Thrombocytopenia (ITP) Market Insights, Epidemiology, and Forecasts, 2017-2028 : Focus on United States, Germany, Spain, Italy, France, and the United Kingdom, and Japan" PRNewswire Genosco
2019-11-04 AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications Molecular Cancer SKI-G-801
2019-11-04 Lazertinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: results from the dose escalation and dose expansion parts of a first-in-human, open-label, multicentre, phase 1-2 study THE LANCET ONCOLOGY Lazertinib
2019-07-01 Abstract 2010 : SKI-G-801, an AXL kinase inhibitor, blocks metastasis and induces anti-tumor immune response in various syngeneic cancer models CANCER RESEARCH SKI-G-801
2019-06-25 Oscotec wins exception policy for continued R&D for new drugs KBR (; Korea Biomedical Review) Oscotec
2019-01-28 Genosco gears up for IPO THE INVESTOR Genosco
2018-11-23 Oscotec`s acute leukemia treatment wins orphan drug status from FDA KBR (; Korea Biomedical Review) SKI-G-801
2018-11-05 Korea`s Yuhan Licenses out Lung Cancer Treatment to Janssen Biotech BusinessKorea Lazertinib
2018-06-11 Yuhan ups investment in biotechs for immuno-oncology drug push THE INVESTOR Yuhan/Lazertinib
Board Pagination Prev 1 2 Next
/ 2
© k2s0o1d6e0s8i2g7n. ALL RIGHTS RESERVED.
Requesting to the server, please wait.